SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intuit, Inc. engages in the provision of business and financial management solutions. It operates through the following segments: Small Business and Self-Employed, Consumer, Credit Karma, and ProTax. The Small Business and Self-Employed segment offers QuickBooks financial and business management online services and desktop software, payroll solutions, payment processing solutions, and financing for small businesses. The Consumer segment includes do-it-yourself and assisted TurboTax income tax preparation products and services. The Credit Karma segment serves consumers with a personal finance platform that provides personalized recommendations of credit cards, home, auto and personal loans, and insurance products, and online savings and checking accounts. The ProTax segment refers to the professional accountants in the U.S. and Canada, who are essential to both small business success and tax preparation and filing. The company was founded by Scott D. Cook and Thomas A. Proulx in March 1983 and is headquartered in Mountain View, CA.

Intuit Inc

Intuit's post-earnings selloff is driven by strong quarterly results being overshadowed by a weak full-year guidance, with community focus on the switch to include stock-based compensation and ongoing fears that AI threatens TurboTax and DIY tax prep. Bulls argue the drop is overdone, while bears point to slowing growth and competitive pressure.

Dick's Sporting Goods, Inc. engages in the retailing of an extensive assortment of authentic sports equipment, apparel, footwear, and accessories. It also offers its products both online and through mobile applications. The company was founded by Richard T. Stack in 1948 and is headquartered in Coraopolis, PA.

Dicks Sporting Goods, Inc.

DKS is trending after a brutal post-earnings selloff triggered by weaker-than-expected results, guided-down full-year outlook, and ongoing drag from the Foot Locker acquisition. Community chatter is sharply split between dip buyers calling it a massive overreaction and shorts expect further downside, with many focusing on the Foot Locker deal as the root problem.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Retail traders are piling into CRML as it leads a strong rare-earth/critical minerals sector move, with the community spotlighting heavy volume, scarce shares, the revised European Lithium merger terms, and a building short-squeeze narrative.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

Community buzz centers on founder Patrick Soon-Shiong teasing a trial combining targeted radiation with an IL-15/Anktiva immune approach, fueling speculation about the SHINE Lu-177 supply connection and a broader BioShield push. Retail traders are also weighing the heavy short interest, catalysts like label expansions and pipeline updates, and the recent move back toward $8 as a key battleground.

Zoom Communications, Inc. engages in the provision of a communications and collaboration platform. It operates through the following geographical segments: Americas, Asia Pacific, and Europe, Middle East, and Africa. The company was founded by Eric S. Yuan in 2011 and is headquartered in San Jose, CA.

Zoom Communications Inc. - Ordinary Shares - Class A

ZM is in focus after its quarterly earnings and guidance landed with mixed sentiment, as a stronger print was outweighed by softer near-term guidance and bearish options flow. The community sees the company's Anthropic investment and AI optionality as possible offsets that could eventually re-risk the story, but traders are debating whether the move is a dip buy or a technical breakdown.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVDA is trending as investors gear up for earnings, debating whether a strong report will finally break the pattern of selling the news after a seven-day losing streak. The buzz is split between bulls calling the valuation discount illogical and concerns raised by OpenAI's custom chip benchmarks.

Nuvation Bio, Inc. is a biopharmaceutical company tackling some of the unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its proprietary portfolio includes six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. The company was founded by David Hung on March 20, 2018 and is headquartered in New York, NY.

Nuvation Bio Inc - Ordinary Shares - Class A

Investors are rallying around NUVB after the FDA granted Fast Track designation to its glioma drug safusidenib, with fresh analyst initiations from Cantor Fitzgerald and JPMorgan amplifying the bullish narrative. Community discussion focuses on the best-in-class potential of IBTROZI and safusidenib, along with growing speculation about a future buyout in a hot oncology M&A environment.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is drawing heavy attention as the oil market gets slammed between fresh Strait of Hormuz deal/reopening headlines and growing accusations that the administration is deliberately jawboning crude prices lower. Traders are split between calling the drop a manipulated fake-out and positioning for a severe supply shortfall, with the community also citing continued tanker missile incidents and multiweek inventories as proof the geopolitical risk premium remains unresolved.

Cybin, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

Helus Pharma Inc.

HELP is trending as retail traders rally around the psychedelic sector, energized by the new CEO's track record and the fully enrolled Phase 3 trial on track for a Q4 readout. The conversation centers on buyout speculation, dilution fears, and the stock's deep-value positioning relative to higher-valued peers.

On Holding AG engages in the development and distribution of sports products such as footwear, apparel, and accessories for high-performance running, outdoor, all-day activities, and tennis. It sells its products worldwide through independent retailers and global distributors, its own online presence, and its own stores. The company was founded by David Allemann, Olivier Bernhard, and Caspar Coppetti in January 2010 and is headquartered in Zurich, Switzerland.

On Holding AG - Ordinary Shares Class A

On Holding AG

ONON is trending after a sharp selloff tied to disappointing guidance and broader weakness across athletic-apparel retailers, with peers like Nike and Dick's Sporting Goods also under pressure. The community is split between bulls highlighting strong margins, DTC growth, and insider buying, and bears pointing to valuation concerns and softer consumer demand.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Abeona Therapeutics Q2 2026 Earnings Call Transcript

Abeona Therapeutics (NASDAQ:ABEO) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call.
This content is powered by Benzinga APIs. For comprehensive financial dataread more...

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Abeona Therapeutics Inc. (NASDAQ: ABEO)

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Abeona Therapeutics Inc. (NASDAQ: ABEO) SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Abeona Therapeutics Inc. (NASDAQ: ABEO) PR Newswire NEW YORK, July 27, 2026 NEW YORK, July 27...

Abeona Therapeutics Q1 2026 Earnings Call: Complete Transcript

Abeona Reports Strong Q1 Revenue, Expands Treatment Center Network

Abeona Therapeutics Inc. (NASDAQ: ABEO) reported first-quarter earnings Wednesday before the market opened. Here's a rundown of the report.read more...

Abeona Therapeutics (ABEO) to Release Quarterly Earnings on Wednesday

Abeona Therapeutics (NASDAQ:ABEO) will be releasing its Q1 2026 earnings before the market opens on Wednesday, May 13. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-13-abeona-therapeutics-inc-stock...

Abeona Therapeutics Inc. (NASDAQ:ABEO) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Shares of Abeona Therapeutics Inc. (NASDAQ:ABEO - Get Free Report) have been given a consensus rating of "Moderate Buy" by the five brokerages that are currently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the c...

2,000,000 Shares in Abeona Therapeutics Inc. $ABEO Purchased by AIGH Capital Management LLC

AIGH Capital Management LLC purchased a new position in Abeona Therapeutics Inc. (NASDAQ:ABEO - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 2,000,000 shares of the biopharmaceutical compa...

Abeona Therapeutics (NASDAQ:ABEO) Share Price Crosses Above 50 Day Moving Average - Here's What Happened

Abeona Therapeutics (NASDAQ:ABEO) Stock Price Crosses Above Fifty Day Moving Average - What's Next...

Aberdeen Group plc Makes New $3.25 Million Investment in Abeona Therapeutics Inc. $ABEO

Aberdeen Group plc acquired a new position in shares of Abeona Therapeutics Inc. (NASDAQ:ABEO - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange...

HC Wainwright Issues Pessimistic Outlook for ABEO Earnings

Abeona Therapeutics Inc. (NASDAQ:ABEO - Free Report) - Equities researchers at HC Wainwright decreased their Q1 2026 EPS estimates for Abeona Therapeutics in a report released on Thursday, March 19th. HC Wainwright analyst R. Selvaraju now anticipates that the biopharmaceutical company will post ear...

Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life-threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA), and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in Cleveland, OH.

Abeona Therapeutics Inc

Abeona Therapeutics’ Gene Therapy Gets FDA Nod For Treating Rare Genetic Skin Disease

Equity

Bearish Sentiment

Rallies more than 5%

Modest gain (0-5%)

Modest decline (0-5%)

Drops more than 5%

Nvidia ($NVDA) reports earnings Wednesday, August 26, with options markets pricing in a roughly 5-7% post-earnings move. How do you think Nvidia's stock reacts to earnings? Vote and explain your reasoning in the comments.

Nvidia ($NVDA) reports earnings Wednesday, with options markets pricing in a 5-7% move. How do you think the stock reacts?

Stocktwits

) reports earnings Wednesday, with options markets pricing in a 5-7% move. How do you think the stock reacts?

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '26	-$0.16	--	--	N/A
Q2 '26	-$0.23	-$0.35	-51.08%	MISSED
Q1 '26	-$0.34	-$0.30	10.45%	BEAT
Q4 '25	-$0.35	-$0.36	-2.27%	MISSED
Q3 '25	-$0.28	-$0.10	64.54%	BEAT

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q2 '26

Historical Earnings